Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.